Association of Hypertension and Hyperhomocysteinemia with Silent Brain Infarction in the Healthy

doi:10.3969/j.issn.1673-5765.2020.08.008

Abstract

Abstract:

Objective To investigate the prevalence of silent brain infarction (SBI) in the health people, and evaluate the association of hypertension (HT) and hyperhomocysteinemia (HHcy) with SBI. Methods The consecutive participants who underwent physical examination in the Health Management Center of Beijing Tiantan Hospitial from September 2018 to June 2019 were enrolled in a cross-section study. The baseline clinical data were collected. MRI was evaluated by radiologists who were blinded to the clinical data. Univariable analysis and multivariable logistic regression analysis were conducted to analyze the correlation of HT and HHcy with SBI. Results A total of 557 eligible participants were included, with a mean age of 52.0±10.4 years and 252 females (43.7%). The prevalence of SBI, only HT and only HHcy were 8.8% (51/577), 20.5% (118/577) and 27.6% (159/577), respectively. The HT concomitant with HHcy occurred in 8.3% (48/577). In the univariable analysis, only HHcy (OR 3.72, 95%CI 1.69-8.18, P =0.002), only HT (OR 5.88, 95%CI 2.59-13.3, P <0.001), HT concomitant with HHcy (OR 7.66, 95%CI 3.20-18.3, P <0.001) all increased the risk of SBI. After adjusting for the confounding factors, the multivariable analysis showed that the only HHcy (OR 2.55, 95%CI 1.06-6.11, P =0.036), only HT (OR 3.97, 95%CI 1.68-9.43, P =0.001), HT concomitant with HHcy (OR 3.64, 95%CI 1.31-10.1, P =0.013) were all associated with SBI. In the univariable analysis, there was interaction between HT and HHcy, while in the multivariable analysis, there was no interaction between them (OR 0.29, 95%CI 0.08-1.09, P >0.05). Conclusions SBI is common in neurological health people. Both HT and HHcy were associated with SBI.

Key words: Silent Brain Infarction; Hypertension; Hyperhomocysteinemia

摘要：

目的调查静止性脑梗死（silent brain infarction，SBI）在健康体检人群中的患病率，分析高血压、高同型半胱氨酸血症（hyperhomocysteinemia，HHcy）与SBI的相关性。方法本研究为单中心横断面研究，前瞻性连续纳入2018年9月-2019年6月既往无明确神经系统疾病的体检者，收集人口学信息，高血压、糖尿病、冠心病等血管危险因素，生活方式及生化检查（包括血浆同型半胱氨酸）等资料。影像学医师采用盲法评价头颅MRI，判断是否存在SBI。按照是否存在高血压和HHcy分为正常、单纯高血压、单纯HHcy、高血压合并HHcy 4组，采用单因素和多因素 Logistic回归分析高血压、HHcy与SBI的相关性。结果共纳入577名受试者，平均年龄52.0±10.4岁，女性252名（43.7%）。SBI患病率为8.8% （51/577），高血压、HHcy的患病率分别为20.5%（118/577）和27.6%（159/577），高血压合并HHcy 的患病率为8.3%（48/577）。单因素分析显示，单纯HHcy（OR 3.72，95%CI 1.69～8.18，P =0.002），单纯高血压（OR 5.88，95%CI 2.59～13.3，P＜0.001），高血压合并HHcy（OR 7.66，95%CI 3.20～18.3，P ＜0.001）均增加SBI风险。校正混杂因素后，单纯HHcy（OR 2.55，95%CI 1.06～6.11，P =0.036），单纯高血压（OR 3.97，95%CI 1.68～9.43，P =0.001），高血压合并HHcy（OR 3.64，95%CI 1.31～10.1， P =0.013）也均与SBI风险升高有关。单因素分析中高血压和HHcy存在交互作用（P＜0.001）；在多因素分析中，高血压和HHcy的交互作用差异无统计学意义（OR 0.29，95%CI 0.08～1.09，P＞0.05）。结论在健康体检人群中，SBI是一种常见头部影像学改变，高血压和HHcy均与SBI相关。

关键词: 静止性脑梗死; 高血压; 高同型半胱氨酸血症

ZHENG Hua-Guang, LIU Xiao-Nan, ZHANG Wei-Wei, ZHANG Long-You, WANG Rui-Qing, MENG Qing-Ying,DUAN Yun-Yun, LIU Ya-Ou, WANG Yong-Jun. Association of Hypertension and Hyperhomocysteinemia with Silent Brain Infarction in the Healthy[J]. Chinese Journal of Stroke, 2020, 15(08): 861-868.

郑华光，刘晓楠，张蔚韡，张龙友，王瑞青，孟庆颖，段芸芸，刘亚欧，王拥军. 高血压和高同型半胱氨酸血症与静止性脑梗死的相关性分析[J]. 中国卒中杂志, 2020, 15(08): 861-868.

References

[1] VERMEER S E，LONGSTRETH W T Jr，

KOUDSTAAL P J. Silent brain infarcts：a systematic

review[J]. Lancet Neurol，2007，6（7）：611-619.

[2] ZHU Y C，DUFOUIL C，TZOURIO C，et al. Silent

brain infarcts：a review of MRI diagnostic criteria[J].

Stroke，2011，42（4）：1140-1145.

[3] KOVÁCS K R，CZURIGA D，BERECZKI D，et.

al. Silent brain infarction--a review of recent

observations[J]. Int J Stroke，2013，8（5）：334-347.

[4] SMITH E E，SAPOSNIK G，BIESSELS G J，et

al. Prevention of stroke in patients with silent

cerebrovascular disease：a scientific statement for

healthcare professionals from the American Heart

Association/American Stroke Association[J/OL].

Stroke，2017，48（2）：e44-e71[2019-12-19].

http：//doi.org/10.1161/STR.0000000000000116.

[5] VERMEER S E，PRINS N D，HEIJER T D，et al.

Silent brain infarcts and the risk of dementia and

cognitive decline[J]. N Engl J Med，2003，348（13）：

1215-1222.

[6] GUPTA A，GIAMBRONE A E，GIALDINI G，et

al. Silent brain infarction and risk of future stroke：a

systematic review and meta-analysis[J]. Stroke，2016，

47（3）：719-725.

[7] CHOI P，REN M，PHAN T G，et al. Silent infarcts

and cerebral microbleeds modify the associations of

white matter lesions with gait and postural stability：

population-based study[J]. Stroke，2012，43（6）：

1505-1510.

[8] SLOTEN T T，SIGURDSSON S，BUCHEM M A，

et al. Cerebral small vessel disease and association with higher incidence of depressive symptoms in

a general elderly population：the AGES-Reykjavik

Study[J]. Am J Psychiatry，2015，172（6）：570-578.

[9] CANNISTRARO R J，BADI M，EIDELMAN B H，

et al. CNS small vessel disease：a clinical review[J].

Neurology，2019，92（24）：1146-1156.

[10] YILMAZ P，IKRAM M K，NIESSEN W J，et al.

Practical small vessel disease score relates to stroke，

dementia，and death[J]. Stroke，2018，49（12）：

2857-2865.

[11] WRIGHT C B，DONG C H，PEREZ E J，et al.

Subclinical cerebrovascular disease increases the

risk of incident stroke and mortality：the Northern

Manhattan Study[J/OL]. J Am Heart Assoc，2017，6

（9）：e004069[2019-12-19]. https：//doi.org/10.1161/

jaha.116.004069.

[12] VERMEER S E，KOUDSTAAL P J，OUDKERK

M，et al. Prevalence and risk factors of silent brain

infarcts in the Population-Based Rotterdam Scan

Study[J]. Stroke，2002，33（1）：21-25.

[13] PRABHAKARAN S，WRIGHT CB，YOSHITA

M，et al. Prevalence and determinants of subclinical

brain infarction：the Northern Manhattan Study[J].

Neurology，2008，70（6）：425-430.

[14] DAS R R，SESHADRI S，BEISER A S，et al.

Prevalence and correlates of silent cerebral infarcts

in the Framingham Offspring Study[J]. Stroke，2008，

39（11）：2929-2935.

[15] FANNING J P，WONG A A，FRASER J F. The

epidemiology of silent brain infarction：a systematic

review of population-based cohorts[J/OL]. BMC Med，

2014，12：119[2019-12-19]. https：//doi.org/10.1186/

s12916-014-0119-0.

[16] FEI H，ZHAI F F，WANG Q，et al. Prevalence and

risk factors of cerebral small vessel disease in a

Chinese population-based sample[J]. J Stroke，2018，

20（2）：239-246.

[17] NAM K W，KWON H M，JEONG H Y，et al. Serum

homocysteine level is related to cerebral small vessel

disease in a healthy population[J/OL]. Neurology，

2019，92（4）：e317-e325[2019-12-19]. https：//doi.

org/10.1212/wnl.0000000000006816.

[18] HOWARD G，WAGENKNECHT L E，CAI J，et al.

Cigarette smoking and other risk factors for silent

cerebral infarction in the general population[J].

Stroke，1998，29（5）：913-917.

[19] NAKANISHI K，JIN Z，HOMMA S，et al. Nighttime

systolic blood pressure and subclinical

cerebrovascular disease：the Cardiovascular

Abnormalities and Brain Lesions（CABL）study[J].

Eur Heart J Cardiovasc Imaging，2019，20（7）：765-

771.

[20] VERMEER S E，DIJK E J，KOUDSTAAL P J，et

al. Homocysteine，silent brain infarcts，and white

matter lesions：the Rotterdam Scan Study[J]. Ann

Neurol，2002，51（3）：285-289.

[21] SESHADRI S，WOLF P A，BEISER A S，et al.

Association of plasma total homocysteine levels with

subclinical brain injury：cerebral volumes，white

matter hyperintensity，and silent brain infarcts

at volumetric magnetic resonance imaging in the

Framingham Offspring Study[J]. Arch Neurol，2008，

65（5）：642-649.

[22] PIKULA A，BEISER A S，DECARLI C，et

al. Multiple biomarkers and risk of clinical and

subclinical vascular brain injury：the Framingham

Offspring Study[J]. Circulation，2012，125（17）：

2100-2107.

[23] LARSSON S C，TRAYLOR M，MARKUS H

S，et al. Homocysteine and small vessel stroke：a

mendelian randomization analysis[J]. Ann Neurol，

2019，85（4）：495-501.

[24] KALANTARIAN S，AY H，GOLLUB R L，et al.

Association between atrial fibrillation and silent

cerebral infarctions. A systematic review and metaanalysis[

J]. Ann Intern Med，2014，161（9）：650-

658.

[25] CHAUHAN C，ADAMS H H H，SATIZABAL

C L，et al. Genetic and lifestyle risk factors

for MRI-defined brain infarcts in a populationbased

setting[J/OL]. Neurology，2019，92（5）：

e486-e503[2019-12-19]. https：//doi.org/10.1212/

wnl.0000000000006851.

[26] PANG H，HAN B，FU Q，et al. Association between

homocysteine and conventional predisposing factors

on risk of stroke in patients with hypertension[J].

Sci Rep，2018，8（1）：3900[2019-12-19]. https：//doi.

org/10.1038/s41598-018-22260-6.

[27] WILLIAMS B，MANCIA G，SPIERING W，et al.

2018 ESC/ESH guidelines for the management of

arterial hypertension[J]. Eur Heart J，2018，39（33）：

3021-3104.

[28] AMERICAN DIABETES ASSOCIATION.

Classification and diagnosis of diabetes：standards of

medical care in diabetes-2019[J/OL]. Diabetes Care，

2019，42（Suppl 1）：S13-S28[2019-12-19]. https：//

doi.org/10.2337/dc19-s002.

[29] KNUUTI J，WIJNS W，SARASTE A，et al. 2019

ESC guidelines for the diagnosis and management of

chronic coronary syndromes[J]. Eur Heart J，2020，41

（3）：407-477.

[30] DING N，SANG Y Y，CHEN J S，et al. Cigarette smoking，smoking cessation，and long-term risk of 3

major atherosclerotic diseases[J]. J Am Coll Cardiol，

2019，74（4）：498-507.

[31] WARDLAW J M，SMITH E E，BIESSELS G J，et

al. Neuroimaging standards for research into small

vessel disease and its contribution to ageing and

neurodegeneration[J]. Lancet Neurol，2013，12（8）：

822-838.

[32] SPRINT Research Group，WRIGHT J T Jr，

WILLIAMSON J D，et al. A randomized trial of

intensive versus standard blood-pressure control[J].

N Engl J Med，2015，373（22）：2103-2116.

[33] SPRINT MIND Investigators for the SPRINT

Research Group，JEFF D WILLIAMSON，

NICHOLAS M PAJEWSKI，et al. Effect of intensive

vs standard blood pressure control on probable

dementia：a randomized clinical trial[J]. JAMA，

2019，321（6）：553-561.

[34] ALBERT C M，COOK N R，GAZIANO J M，et

al. Effect of folic acid and B vitamins on risk of

cardiovascular events and total mortality among

women at high risk for cardiovascular disease：a

randomized trial[J] JAMA，2008，299（17）：2027-

2036.

[35] HUO Y，LI J P，QIN X H，et al. Efficacy of folic

acid therapy in primary prevention of stroke among

adults with hypertension in China：the CSPPT

randomized clinical trial[J]. JAMA，2015，313（13）：

1325-1335.

[36] QIN X H，HUO Y. H-type hypertension，stroke

and diabetes in China：opportunities for primary

prevention[J]. J Diabetes，2016，8（1）：38-40.

[37] SPENCE J D，YI Q，HANKEY G J. B vitamins

in stroke prevention：time to reconsider[J]. Lancet

Neurol，2017，16（9）：750-760.

[38] HANKEY G J. B vitamins for stroke prevention[J].

Stroke Vasc Neurol，2018，3（2）：51-58.